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The complete genome sequence of a Mexican West
Nile virus isolate, TM171-03, included 46 nucleotide
(0.42%) and 4 amino acid (0.11%) differences from the
NY99 prototype. Mouse virulence differences between
plaque-purified variants of TM171-03 with mutations at the
E protein glycosylation motif suggest the emergence of an
attenuating mutation.
S
ince its introduction into North America in 1999, West
Nile virus (WNV) has spread rapidly across the conti-
nent, and evidence for virus circulation has also been
detected in the Caribbean and parts of Central America (1).
In 2003, WNV was isolated from a dead raven in
Villahermosa, in the state of Tabasco, Mexico (2).
Nucleotide sequencing of the premembrane (prM) and
envelope (E) structural protein genes of this strain,
TM171-03, and comparison with sequences from other
North American isolates indicated that this virus had accu-
mulated several unique mutations from the New York 1999
strain 382-99 (NY99) prototype sequence. We describe the
complete genomic sequence of TM171-03 and its relation-
ship to other North American isolates, as well as the results
of virulence phenotype comparisons.
The Study 
The isolation and initial characterization of TM171-03
have been described elsewhere (2). For genomic sequenc-
ing, RNA was extracted from infected Vero cell culture
supernatant (second Vero cell passage from the original
brain material, designated V2) using the QiaAmp kit
(Qiagen Inc., Valencia, CA), reverse transcribed with
AMV reverse transcriptase (RT) (Roche, Indianapolis, IN)
and amplified by polymerase chain reaction (PCR) as nine
overlapping fragments by using Taq polymerase (Roche).
The PCR products were purified from 1.5% TAE/agarose
gels by using the QiaQuick kit (Qiagen) and directly
sequenced on an ABI Prism model 3100 DNA sequencer
(Applied Biosystems, Foster City, CA) at the University of
Texas Medical Branch’s Protein Chemistry Core Facility
by using the amplifying primers and additional internal
primers. The primers used for RT-PCR and sequencing
were similar to those used by Lanciotti et al. (3) and
Beasley et al. (4) (complete details are available on
request). Sequence data were assembled into the complete
genome sequence and analyzed as described elsewhere
(2,4). In addition, Bayesian analyses were performed by
using MRBAYES v3.0 (5) and 100,000 generations. A
general time-reversible model was used with empirically
estimated base frequencies and either a codon position-
specific or a γ distribution of substitution rates.
The genomic sequence for TM171-03 (GenBank acces-
sion number AY660002) differed from the NY99 prototype
sequence (GenBank AF196835) at 46 nucleotides (nt)
(0.42%). As reported previously, sequencing the prM-E
genes of TM171-03 (V1 passage) identified nonsynony-
mous mutations encoding substitutions at prM-141
Ile→Thr and E156 Ser→Pro (2). The E-156 mutation
results in the loss of the E-154-156 “NYS” glycosylation
motif. Complete genome sequencing identified only two
other encoded amino acid changes from the NY99 sequence
at NS4B-245 (Ile→Val) and NS5-898 (Thr→Ile). However,
during the sequencing of the V2 passage material, a rever-
sion from Pro to Ser encoded at E-156 was observed.
Analysis of the sequence chromatograms from V1 and V2
passages, and for a PCR product obtained from the original
brain material, indicated that this reversion was likely to be
the result of a mixed virus population, with overlapping “T”
and “C” peaks visible at residue 1432 in the sense or anti-
sense sequences for each product. To confirm this finding,
PCR products containing the E-156 region from each pas-
sage level of TM171-03 were cloned into pGEM-T(Easy)
(Promega, Madison, WI), and five clones were sequenced
for each. For the original brain tissue, four clones encoded
Pro at E-156 and one clone encoded Ser. For products
derived from either V1 or V2 passages, two or three clones
encoded a Pro at E-156, and the remainder encoded a Ser.
In addition, several variants of TM171-03 were purified
through two rounds of plaque selection in Vero cells, and
nucleotide sequencing of these variants also confirmed a
mixed population. Sequences from approximately half of
the plaques encoded a Pro at E-156, while the remainder
encoded Ser. Western blotting of infected Vero cell lysate
antigens for these variants with WNV E protein-specific
monoclonal antibody 7H2 (6) showed differences in the
electrophoretic mobility of the proteins consistent with the
presence or absence of glycosylation (Figure 1).
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Mexico City, Mexico Comparison of the TM171-03 nucleotide sequence with
other genomic sequences of WNV strains showed that it
was most closely related to strain NY00-grouse3282
(GenBank AF404755; Figure 2). The NY00-grouse3282
sequence differed from NY99 at only 13 nt (0.11%), and
its relationship to TM171-03 was apparently based on 10
nonstructural protein region nucleotide differences from
NY99 that were shared with TM171-03 (Table 1). None of
these mutations encoded amino acid differences, and
TM171-03 differed from NY00-grouse3282 at 39 other
nucleotides. These were primarily additional mutations
that had accumulated in the TM171-03 strain. Genomic
sequence data from other East Coast U.S. isolates collect-
ed during 2000 and subsequent years are needed to attempt
to establish a definitive relationship for TM171-03 with a
particular North American isolate.
To assess the effects of the E-156 Ser→Pro mutation on
the virulence of TM171-03, serial 10-fold doses from
1,000 to 0.1 PFU of TM171-03 and four plaque-purified
(pp) substrains (TM171-03-pp1 and -pp2 encoding Pro at
E-156; TM171-03-pp5 and -pp6 encoding Ser) were inoc-
ulated intraperitoneally (i.p.) and intracranially (i.c.) into
groups of 3- to 4-week-old female NIH Swiss mice to
determine mouse neuroinvasiveness and neurovirulence,
as described elsewhere (7) and in accordance with guide-
lines of the University of Texas Medical Branch
Institutional Animal Care and Use Committee.
TM171-03 was highly virulent following i.p. and i.c.
inoculation, as were the plaque-purified variants, TM171-
03-pp5 and -pp6, which encoded the E154-156 NYS gly-
cosylation motif (i.p. and i.c. 50% lethal dose [LD50]
values for each <2.0 PFU; Table 2). The lethality of these
strains was comparable to that of other North American
isolates that have been evaluated by using the NIH Swiss
mouse model (4,7). In contrast, the nonglycosylated vari-
ants TM171-03-pp1 and -pp2 were both attenuated, having
i.p. LD50 values >1,000 PFU and i.c. LD50 values of 32 and
25 PFU, respectively. 
To confirm that the mouse virulence differences
between the plaque-purified variants could be primarily
attributed to the mutation at E-156, regions that encoded
the additional consensus amino acid mutations at prM-141,
NS4B-245, and NS5-898 were sequenced. All four plaque-
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Figure 1. Western blot showing differing mobility of E proteins from
nine plaque-purified variants of West Nile virus (WNV) strain TM-
171 Mex03. Nucleotide sequencing of strains in lanes 5 to 9 indi-
cated the presence of an "NYS" glycosylation motif at residues
154 to 156 of E, while strains in lanes 1 to 4 encoded "NYP."
Antigens were separated in a nonreducing 5%/10% discontinuous
sodium dodecyl sulfate-polyacrylamide gel, transferred to 0.2 µm
nitrocellulose and detected with WNV-specific monoclonal anti-
body 7H2 (6).purified variants encoded the three amino acid mutations
that were present in the consensus sequence. No addition-
al mutations encoding amino acid changes were identified
in the regions that were sequenced for these strains (equiv-
alent to ≈3,000 nt in total for each). Although the entire
genome of each plaque-purified variant was not
sequenced, we believe that it is highly unlikely that the
mouse virulence differences observed between the variants
would be attributable to other amino acid mutations in the
unsequenced regions that were present in the two E-156
Pro variants but not the E-156 Ser variants or the parental
TM171-03 strain. 
Conclusions
These results are somewhat contrary to previously
reported data that described attenuated variants with gly-
cosylated E proteins that were derived from a virulent,
nonglycosylated Israeli lineage 1 WNV strain (8).
However, subsequent studies identified E glycosylated
variants of the same strain that retained a virulent pheno-
type, which suggests that multiple determinants, most
probably including mutations in the nonstructural protein
genes, were responsible for the observed variations in vir-
ulence (9). Other comparisons of wild-type WNV strains
suggested that absence of E protein glycosylation might be
associated with attenuation of mouse neuroinvasiveness
(7). Recently, some of us have shown that mutating the E
protein gene of a WNV infectious clone derived from the
NY99 prototype strain to prevent glycosylation resulted in
a ≈200-fold attenuation of neuroinvasiveness, but not neu-
rovirulence, in the NIH Swiss mouse model (D.W.C.
Beasley, et al., unpub. data). Given the greater degree of
attenuation of neuroinvasiveness and neurovirulence
observed for the nonglycosylated TM171-03-pp1 and -pp2
variants described here, we hypothesize that one or more
of the other mutations (at prM-141, NS4B-245, or NS5-
898) also contributed to the phenotype, but this hypothesis
remains to be determined experimentally. All of these
mutations in the absence of the E-156 Ser→Pro mutation
(as occurred in the TM171-03-pp4 and -pp5 variants) did
not appear to significantly affect the mouse virulence phe-
notype. 
E protein glycosylation appears to play an important
role in flavivirus assembly in mammalian cell culture (10);
the mechanism by which this particular mutation would
emerge in a wild-type WNV population, as is the case with
the TM171-03 isolate, is not clear. However, the posttrans-
lational processing of glycoproteins differs between mos-
quito and mammalian cells (11), and adaptation of dengue
virus to mosquito cells resulted in loss of the equivalent
glycosylation motif (12), which suggests that the presence
of carbohydrate on the E protein may be of lesser impor-
tance during virus replication in mosquito cells.
Recent data from the Mexican Department of Health
indicate that no human cases of encephalitis attributable to
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Figure 2. Neighbor-joining phylogenetic tree based on complete
genome sequences of West Nile virus strains. Strain TM171-03 is
indicated in bold text. The topology of maximum parsimony and
maximum likelihood trees was essentially identical. Bayesian
analysis also confirmed the close relationship between TM171-03
and NY00-grouse3282 sequences (data not shown). Bootstrap
values are shown for major branches (500 replicates). GenBank
accession numbers for sequences used to construct the tree are
indicated on the branches. local transmission of WNV have occurred during 2004
and, although many WNV-seropositive horses have been
identified, few cases of overt clinical disease have been
reported (http://www.cenave.gob.mx/von; accessed 26
Aug, 2004). The epidemiology of WNV disease in Mexico
is likely to be complicated by preexisting immunity to
other flaviviruses, but the emergence of an attenuated
WNV strain would be important. WNV nucleotide
sequences obtained from infected horses in Mexican states
closer to the U.S. border suggest that they are closely relat-
ed to recent isolates from Texas that do not encode muta-
tions at the E glycosylation motif (13; J. Estrada-Franco, et
al., unpub. data).We are unaware of any other WNV iso-
lates from Tabasco or other southern regions of Mexico.
Obtaining additional isolates from southern Mexico is
important to determine if a nonglycosylated WNV popula-
tion is emerging and to ascertain what impact this may
have on the prevalence of severe WNV disease in Mexico.
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